LEU006

LEU006 is an investigational chimeric antigen receptor (CAR) T-cell therapy being developed by Leucid Bio for the treatment of solid malignancies. Currently in the preclinical stage of development, the specific molecular target of the CAR-T construct has not been disclosed by the company. LEU006 is part of Leucid Bio's pipeline of next-generation cell therapies designed to overcome the challenges of the immunosuppressive tumor microenvironment in solid tumors. The therapy likely utilizes the company's proprietary 'Lateral CAR' platform, which reconfigures the signaling endodomains to enhance T-cell activation, persistence, and anti-tumor efficacy compared to traditional CAR architectures.